Abstract
Background: The lung is the most common single site of origin of
neuroendocrine cancers, and lung neuroendocrine tumor (LNET)
incidence and prevalence is rising. There is a lack of both LNET-specific
data and up to date clinical guidance. Management of LNETs often
relies on extrapolation from other tumor sites. The Commonwealth
Neuroendocrine Tumour Collaboration (CommNETS) and North
American Neuroendocrine Tumor Society (NANETS) sought to
consider current data and provide updated guidance on LNET diagnosis
and management.
Method: The latest best practice consensus
on LNETs was published by the European Neuroendocrine Tumor
Society (ENETS) in 2015. A review of content and methods using the
AGREE II Rigour of Development subscale (www.agreetrust.org)
confirmed the quality of the ENETS initiative, providing a basis for
endorsement and update. A systematic literature search was conducted
and a 22 member, multidisciplinary CommNETS/NANETS
expert panel endorsed or modified recommendations from a patientcentered
perspective. All statements were graded using Oxford
criteria (CEBM.net).
Result: A total of 230 studies were identified for
consideration by the panel. Recommendations were modified or
added to reflect clinical data not available in 2015. Out of the 52
ENETS statements, 40% were endorsed, 58% were modified or
updated, one was removed and four were added. Themes identified in
the consensus update include new statements, practice changing
modifications, augmented grades of recommendation and statement
refinements, each addressing specialties ranging from epidemiology,
pathology and diagnosis to treatment and follow-up (Table 1). The
importance of LNET directed research and patient-centered care
throughout the treatment trajectory is also emphasized, along with
directions for future research.
Conclusion: Ongoing collaboration is
essential for future development of updated LNET clinical guidance
and to direct research efforts in a patient-centered context. Our
consensus update demonstrates international collaboration to
develop guidance on clinical management of malignancies for which
limited data are available
neuroendocrine cancers, and lung neuroendocrine tumor (LNET)
incidence and prevalence is rising. There is a lack of both LNET-specific
data and up to date clinical guidance. Management of LNETs often
relies on extrapolation from other tumor sites. The Commonwealth
Neuroendocrine Tumour Collaboration (CommNETS) and North
American Neuroendocrine Tumor Society (NANETS) sought to
consider current data and provide updated guidance on LNET diagnosis
and management.
Method: The latest best practice consensus
on LNETs was published by the European Neuroendocrine Tumor
Society (ENETS) in 2015. A review of content and methods using the
AGREE II Rigour of Development subscale (www.agreetrust.org)
confirmed the quality of the ENETS initiative, providing a basis for
endorsement and update. A systematic literature search was conducted
and a 22 member, multidisciplinary CommNETS/NANETS
expert panel endorsed or modified recommendations from a patientcentered
perspective. All statements were graded using Oxford
criteria (CEBM.net).
Result: A total of 230 studies were identified for
consideration by the panel. Recommendations were modified or
added to reflect clinical data not available in 2015. Out of the 52
ENETS statements, 40% were endorsed, 58% were modified or
updated, one was removed and four were added. Themes identified in
the consensus update include new statements, practice changing
modifications, augmented grades of recommendation and statement
refinements, each addressing specialties ranging from epidemiology,
pathology and diagnosis to treatment and follow-up (Table 1). The
importance of LNET directed research and patient-centered care
throughout the treatment trajectory is also emphasized, along with
directions for future research.
Conclusion: Ongoing collaboration is
essential for future development of updated LNET clinical guidance
and to direct research efforts in a patient-centered context. Our
consensus update demonstrates international collaboration to
develop guidance on clinical management of malignancies for which
limited data are available
| Original language | English |
|---|---|
| Pages (from-to) | S575 |
| Number of pages | 1 |
| Journal | Journal of Thoracic Oncology |
| Volume | 13 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - Oct 2018 |
